Literature DB >> 22035707

Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation.

Don Hayes1, Jasleen Kukreja, Joseph D Tobias, Hubert O Ballard, Charles W Hoopes.   

Abstract

Venovenous extracorporeal membrane oxygenation (VV ECMO) is a therapeutic option to bridge patients with advanced lung disease to lung transplantation. The use of VV ECMO avoids the use of mechanical ventilation while allowing patients to participate in physical therapy and to eat normally while receiving respiratory support. We describe the successful use of ambulatory single-venous VV ECMO as a bridge to bilateral lung transplantation in 4 patients with end-stage lung disease due to cystic fibrosis who developed acute hypercapnic respiratory failure. The use of ambulatory single-venous VV ECMO was safe and effective in this small cohort of CF patients. Based on our experiences, our belief is that a key step in the treatment course was early application of VV ECMO soon after development of acute respiratory failure requiring mechanical ventilation.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22035707     DOI: 10.1016/j.jcf.2011.07.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  21 in total

Review 1.  Spontaneous breathing during veno-venous extracorporeal membrane oxygenation.

Authors:  Stefania Crotti; Nicola Bottino; Elena Spinelli
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 2.  Ambulatory veno-venous extracorporeal membrane oxygenation.

Authors:  Jonas Andersson Lindholm
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Fourteen Day In Vivo Testing of a Compliant Thoracic Artificial Lung.

Authors:  David J Skoog; Joshua R Pohlmann; David S Demos; Christopher N Scipione; Amit Iyengar; Rebecca E Schewe; Ahmed B Suhaib; Kelly L Koch; Keith E Cook
Journal:  ASAIO J       Date:  2017 Sep/Oct       Impact factor: 2.872

4.  Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation.

Authors:  Matthew Adam Schechter; Asvin M Ganapathi; Brian R Englum; Paul J Speicher; Mani A Daneshmand; R Duane Davis; Matthew G Hartwig
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

5.  Awake extracorporeal membrane oxygenation in patients with severe postoperative acute respiratory distress syndrome.

Authors:  Hye Ju Yeo; Woo Hyun Cho; Dohyung Kim
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

6.  Extracorporeal membrane oxygenation with spontaneous breathing as a bridge to lung transplantation.

Authors:  Mario Nosotti; Lorenzo Rosso; Davide Tosi; Alessandro Palleschi; Paolo Mendogni; Ilaria Faustina Nataloni; Stefania Crotti; Paolo Tarsia
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-24

7.  Extracorporeal membrane oxygenation and retransplantation in lung transplantation: an analysis of the UNOS registry.

Authors:  Don Hayes; Robert S Higgins; Ahmet Kilic; Stephen Kirkby; Amy L Pope-Harman; Thomas J Preston; Bryan A Whitson
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

Review 8.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

9.  Survival of patients with cystic fibrosis on ECMO: analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Don Hayes; Benjamin T Kopp; Thomas J Preston; Stephen Kirkby; Joseph D Tobias; Thomas J Papadimos; Bryan A Whitson
Journal:  Int J Clin Exp Med       Date:  2014-05-15

10.  Active rehabilitation with venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation in a pediatric patient.

Authors:  Don Hayes; Patrick I McConnell; Thomas J Preston; Andrew R Yates; Stephen Kirkby; Mark Galantowicz
Journal:  World J Pediatr       Date:  2013-11-14       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.